Leslie V. Norwalk, serving as a director at Neurocrine Biosciences Inc (NASDAQ:NBIX), recently disposed of 1,250 shares of the company's common equity on June 4, 2026. The transaction resulted in total proceeds of $210,071. The shares were liquidated at prices fluctuating between $168.00 and $168.2550 per share, yielding a weighted average sales price of $168.0573. This disposition occurred in close proximity to the stock's 52-week high of $169.57, a period marked by a substantial 30% gain over the preceding year that expanded the company's market capitalization to $16.4 billion.
The transaction was facilitated by a broker operating under the parameters of a Rule 10b5-1 trading plan. This pre-arranged framework was adopted and became effective on September 15, 2025. Corporate governance protocols strictly prohibit the reporting individual from amending or modifying any established 10b5-1 trading plan following its adoption. Post-transaction, Norwalk maintains direct ownership of 2,838 shares of Neurocrine Biosciences common stock. Independent analysis suggests the equity may remain undervalued despite recent upward momentum, prompting investor interest in comprehensive research reports for deeper valuation insights.
Concurrently, Neurocrine Biosciences is advancing its clinical pipeline with promising clinician-reported data regarding its treatment for tardive dyskinesia. Presented at a conference in Dallas, the data underscored notable improvements in symptom severity among patients receiving INGREZZA (valbenazine) capsules. In strategic developments, Goldman Sachs recently resumed coverage on Neurocrine Biosciences, assigning a buy rating. The firm cited the completion of the Soleno Therapeutics acquisition as a catalyst for medium-term revenue growth. This acquisition introduces Vykat XR, a therapy for Prader-Willi syndrome, into the company's commercial portfolio.
Further bolstering the outlook, Bernstein initiated coverage on Neurocrine with an outperform rating. The firm acknowledged the robust potential of the company's core medicines, Crenessity and Ingrezza, noting their respective loss-of-exclusivity dates in 2035 and 2038. Looking ahead, Neurocrine is scheduled to present two-year clinical data on CRENESSITY at the Endocrine Society's annual meeting in 2026. These presentations will encompass long-term extension studies addressing classic congenital adrenal hyperplasia in both adult and pediatric populations.
Market dynamics in the neurology sector also show positive trends. Morgan Stanley tracking data indicates a year-over-year increase in US antipsychotic prescriptions, reflecting broader momentum in the field. Investors assessing NBIX may find value in evaluating its fundamentals, momentum, and valuation through AI-driven strategies that analyze thousands of companies using over 100 financial metrics. These strategies aim to identify stocks offering optimal risk-reward profiles based on current data, highlighting past successes in sectors like technology and biotech.